Olema Pharmaceuticals Inc

Olema’s VP of Finance buys 11,700 shares at zero cost – a bullish insider signal before key OPERA‑01 results, suggesting upside amid current lows.

Olema Pharmaceuticals’ new stock‑option deal signals executive confidence in its women’s‑cancer pipeline and sets a $36 target that could boost shareholder value.

Insider sale by Olema COO Shane Kovacs after JP Morgan event: routine liquidity move, not a warning, as the company’s women’s‑cancer pipeline stays strong.

Insider selling at Olema Pharmaceuticals signals potential caution for investors amid a sharp rally, raising questions about future pipeline prospects.